The impact of Oxytocin (OT) on social cogntion in Schizophrenia.

Phase 3

Completed

• Conditions: Schizophrenia; Mental Health - Schizophrenia

• Registration Number: ACTRN12609000528257
• Lead Sponsor: niversity of Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-07-02
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 40

Inclusion Criteria

Adult males with a primary diagnosis of schizophrenia as determined by interview on the Diagnostic INterview for Psychoses (DIP) and symptoms as assessed by the Positive and Negative Syndrome Scale (PANSS)

Exclusion Criteria

Participants will be excluded if they meet Diagnostic and Statistical Manual
of Mental Disorders (DSM-IV) criteria for current alcohol or substance dependence (other than nicotine) within the last 6 months, have medical conditions that preclude participation in drug trials (including significant brain, cardiac, liver, lung, endocrinological or metabolic disorders) and if their Intelligence Quotient (IQ) falls below 75. Participants must be stabilised on medication for a period of 8 weeks. No females are included in this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Performance on Reading the Mind in the Eyes Test[45 minutes post drug administration at week 1 and at week 2 drug administration.]

Secondary Outcome Measures

Name	Time	Method
Eye-gaze duration and fixation as assessed by a Tobii Eye Tracker when viewing faces[45 minutes post drug administration at week 1 and at week 2 drug administration.];Performance on the Facial Expressions of Emotions (FEEST)[45 minutes post drug administration at week 1 and at week 2 drug administration.];Performance on the False-Belief Picture Sequencing Task[45 minutes post drug administration at week 1 and at week 2 drug administration.];Performance on the Hinting Task[45 minutes post drug administration at week 1 and at week 2 drug administration.];Performance on the Internal, Personal and Situational Attributions Questionnaire[45 minutes post drug administration at week 1 and at week 2 drug administration.];Performance on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)[45 minutes post drug administration at week 1 and at week 2 drug administration.]